GENFIT S A/ADR (NASDAQ:GNFT) has been given a consensus rating of “Buy” by the seven ratings firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $52.62.
A number of research analysts recently issued reports on the company. Leerink Swann initiated coverage on GENFIT S A/ADR in a research report on Wednesday, April 24th. They set an “outperform” rating and a $25.47 price objective for the company. Barclays assumed coverage on GENFIT S A/ADR in a research note on Monday, April 22nd. They set an “overweight” rating and a $55.00 price target for the company. HC Wainwright decreased their price target on GENFIT S A/ADR to $72.00 and set a “buy” rating for the company in a research note on Monday, April 22nd. Zacks Investment Research upgraded DLH from a “sell” rating to a “hold” rating in a research note on Tuesday, July 9th. Finally, Svb Leerink assumed coverage on GENFIT S A/ADR in a research note on Wednesday, April 24th. They set an “outperform” rating and a $58.00 price target for the company.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Dean Capital Investments Management LLC bought a new position in shares of GENFIT S A/ADR in the 1st quarter worth $650,000. TT International purchased a new stake in shares of GENFIT S A/ADR during the 1st quarter worth approximately $1,200,000. Victory Capital Management Inc. purchased a new stake in shares of GENFIT S A/ADR during the 1st quarter worth approximately $2,358,000. Finally, One68 Global Capital LLC purchased a new stake in shares of GENFIT S A/ADR during the 1st quarter worth approximately $270,000. Institutional investors own 14.67% of the company’s stock.
Shares of GNFT stock traded down $0.77 during mid-day trading on Friday, reaching $18.34. The stock had a trading volume of 83,000 shares, compared to its average volume of 112,600. The firm’s 50-day moving average is $20.69. GENFIT S A/ADR has a 12-month low of $18.24 and a 12-month high of $26.25.
GENFIT S A/ADR Company Profile
Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, and autoimmune or fibrotic diseases affecting primarily the liver and gastro-enterology. The company's lead products include Elafibranor, which is in pivotal Phase 3 clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as in Phase 2 study in patients with primary biliary cholangitis; and Nitazoxanide that is in Phase 2 proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis.
Further Reading: What is meant by a buy rating?
Receive News & Ratings for GENFIT S A/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GENFIT S A/ADR and related companies with MarketBeat.com's FREE daily email newsletter.